Recent investigational advances in the management of relapsed/refractory myeloma

Paul Richardson

Prof Paul Richardson (Dana-Farber Cancer Institute, Boston, MA) summarises of results of clinical trials in the management of relapsed or refractory multiple myeloma presented at the 2014 American Society of Hematology (ASH) Annual Meeting.

Investigational agents discussed include: proteasome inhibitor, carfilzomib; anti-CD38 monoclonal antibody, daratumumab: anti-SLAMF7 monoclonal antibody, elotuzumab; histone deacetylase (HDAC) inhibitor, panobinostat; HDAC6 inhibitor, ricolinostat; immunomodulatory agent, pomalidomide.

Share this video  
Similar topics
Related videos
1:45
Clinical translation of carfilzomib trial data for MM treatment
Greg Friberg
2:10
Overview of a Phase II clinical trial of isatuximab
Joseph Mikhael
9:41
Exciting new developments in multiple myeloma
Daniel Auclair et al.
2:07
ASPIRE update: promising results for MM
Alberto Rocci
4:48
The question of drug combinations for consolidation and maintenance for multiple myeloma
Laurent Garderet
Multiple Myeloma
Carfilzomib, Daratumumab, Elotuzumab, Panobinostat, Pomalidomide, Ricolinostat
ASH 2014
Interview
6th December 2014
More from Paul Richardson
Defibrotide to treat hepatic veno-occlusive disease/sinusoidal obstruction syndrome in AML & ALL
Key studies on multiple myeloma presented at ASH 2016
Elotuzumab for the treatment of multiple myeloma
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals